Lurasidone: 9 agencies, 2014–2024
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
No agency in this archive has refused lurasidone: all 9 decisive outcomes across 7 agencies were positive or positive with restrictions.
Assessment has run over 9.8 years, from 2 Jul 2014 at ZIN (Netherlands) to 2 May 2024 at HIRA (South Korea).
AOTMIT (Poland) changed its position: recommended on 10 Apr 2018, restricted by 16 Sep 2021.
No assessment is on file from HAS (France), PHARMAC (New Zealand) and CIPM (Spain), each among the eight highest-volume agencies here.
1 of these 11 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
ZIN (Netherlands) was first to assess lurasidone, on 2 Jul 2014; HIRA (South Korea) did not open a file until 2 May 2024 — an unusually long tail of 9.8 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 6 years in total.
Restriction is doing real work here: 5 of 9 decisive outcomes narrowed lurasidone to a subgroup rather than accepting or refusing it outright, at AOTMIT (Poland), HIRA (South Korea) and SMC (Scotland) among others.
AOTMIT (Poland) is the only agency to have returned to lurasidone, recording 3 separate entries.
9 of the 18 agencies in this archive hold a record for lurasidone.
The full ledger for lurasidone reads 5 restricted, 4 recommended, 1 no benefit and 1 advice.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HIRA (South Korea) | 2 May 2024 | 조현병 및 제 1 형 양극성 장애와 관련된 주요 우울 삽화 | reimbursable only at the evaluated price | source |
| AWMSG (Wales) | 17 Mar 2021 | Treatment of schizophrenia in adults and adolescents aged 13 years and over | recommended (licence extension for paediatric use) | source |
| CHUIKYO (Japan) | 20 May 2020 | ラツーダ錠２０ｍｇ | listed on the NHI price list · 56 days after PMDA approval | source |
| AOTMIT (Poland) | 10 Apr 2018 | Latuda reimbursement recommendation | recommended | source |
| PBAC (Australia) | 2015 | Schizophrenia | The PBAC recommended the listing of lurasidone tablets as an Authority Required (Streamlin… | source |
6 further decisions for lurasidone, across 5 agencies, are not shown here. They link to 6 further source documents.
Related molecules
- aripiprazole — same ATC class N05A — Psycholeptics
- risperidone — same ATC class N05A — Psycholeptics
- paliperidone — same ATC class N05A — Psycholeptics
- olanzapine — same ATC class N05A — Psycholeptics
- quetiapine — same ATC class N05A — Psycholeptics
- droperidol — same ATC class N05A — Psycholeptics
Coverage: 11 decisions for lurasidone from 9 agencies, 2014 to 2024. Data to 7 Sep 2026. ATC class N05A — Psycholeptics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.